曲美他嗪对不稳定型心绞痛患者血管内皮功能的保护作用

目的：观察曲美他嗪对不稳定型心绞痛（UAP）患者的血管内皮功能的保护作用，并探讨其机制。方法：63例UAP患者，被随机分为常规治疗组（30例）和曲美他嗪组（33例），常规治疗组给予扩冠、抗凝、调血脂等治疗，曲美他嗪组在常规治疗基础上加用曲美他嗪20mg，3次／d，服用3个月。并于服药前后分别测定血浆高敏C-反应蛋白（hs—CRP）、血管假性血友病因子（vWF）及肱动脉内皮依赖的舒张功能（FMD），其结果与常规治疗组进行比较。结果：血浆hs—CRP、vWF浓度：治疗前常规治疗组和曲美他嗪组的较健康对照组（14．23±7．44）mg／L，（14．21±7．38）mg／L：（3．05±1．21）mg／L；（190．55±27．34）％，（191．22±26．59）％：（122．74±14．88）Voo]显著升高（P〈0．01）；治疗后常规治疗组的明显降低（P〈0．05），曲美他嗪组的非常显著降低（7．59±6．07）mg／L，（161．05±21．85）％，P〈0．011，较常规治疗组降低更加显著（P〈0．05）。治疗前FMD：常规治疗组和曲美他嗪组的较健康对照组明显降低（6．04±1．16）％，（6．06±1．22）％：（8．55±1．22）％，P〈0．01]；治疗后常规治疗组的明显升高（P〈0．05），曲美他嗪组非常显著升高（7．98±1．26）％，P〈0．01]，较常规治疗组升高更加显著（P〈0．05）。结论：曲美他嗪具有一定的保护血管内皮功能、减轻血管炎症反应的作用。

Protection effect of trimetazidine therapy on vascular endothelial function in patients with unstable angina pectoris

Objective： To observe protection effect of trimetazidine therapy on vascular endothelial function in patients with unstable angina pectoris （UAP）, and study its mechanism. Methods： The 63 UAP patients were randomly divided into routine therapy group and trimetazidine-group. The routine therapy group was received routine therapy fpr UAP. The trimetazidine 20 rag, 3 times daily were given to each cases of trimetazidine group besides routine therapy. The plasma high-sensitive C-reactive protein （hs--CRP） and yon Willebrand factor （vWF） and brachial artery blood flow mediated endothelium-dependent dilation （FMD） were detect before and 3 months after treatment. Its results were compared with health control group. Results： Befor therapy the plasma hs-CRP and vWF content of routine therapy group and trimetazidine group significantly increased compared with health control group 1- （14.23± 7.44） mg/L, （14.21±7.38） mg/L： （3.05±1.21） mg/L, （190. 55 ± 27. 34）% , （191. 22±26. 59）% ： （122.74±14.88） %, P〈0.01]. after therapy plasma hs--CRP and vWF of routine therapy group decreased significantly （P〈 0.05）, of trimetazidine group decreased very significantly （7.59±6.07） rag/L, （161.05±21.85）%, P〈0. 01], those of trimetazidine group decreased more than those of routine therapy group （P〈0.05）. Before therapy brachial artery FMD of routine therapy group and trimetazidine group significantly decreased compared with that of health control group （6.04±1. 16）%, （6.06±1.22）%; （8.55_±1.22）%, P〈0.01], after therapy FMD of routine therapy group increased significantly （P〈0.05）, of trimetazidine group increased very significantly （7. 98±1.26） %, P〈 0.01], that of trimetazidine group inecreased more than that of routine therapy group （P〈0. 05）. Conclusion.. Trimetazidin can improve vascular endothelial function and decrease inflammation reaction.